Spero Therapeutics (SPRO) provided a corporate update regarding interim changes to its leadership and Board as well as an enrollment update regarding the Phase 3 PIVOT-PO trial of Tebipenem HBr. Effective today, the Board of Directors has appointed Esther Rajavelu to serve as Interim President and Chief Executive Officer, stepping in for Sath Shukla, who has agreed to a voluntary paid administrative leave for an interim period. During such leave, Shukla will continue to serve as a member of the Board. The Board has also appointed Director Frank Thomas to serve as Chairman of the Board, stepping in for Dr. Ankit Mahadevia. Dr. Mahadevia will continue to serve as a member of the Board. These leadership changes were implemented as part of the Company’s response to a “Wells Notice” from the Securities and Exchange Commission, related to certain public disclosures by the Company from March 31, 2022 leading up to May 3, 2022.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRO:
- Spero Therapeutics downgraded at Evercore on lack of capital allocation clarity
- Spero Therapeutics downgraded to In Line from Outperform at Evercore ISI
- Spero Therapeutics downgraded to Hold from Buy at TD Cowen
- Spero Therapeutics: Strategic Shift and Earnings Update
- Spero Therapeutics reports Q3 EPS (32c), consensus (36c)